If you're asking whether BPC-157 and TB-500 are banned in sport, two November 2026 fitness outlets say yes: both report that the 2026 WADA prohibited list bans them. The new HHS peptide policy doesn't change that. It's a draft enforcement policy about pharmacies compounding six peptides, and Men's Fitness reports that a prescription does not make a substance permissible for tested athletes.
Below you'll find what the HHS policy covers, what it means if you're tested, what the research shows, and the questions to take to your team physician.
Disclosure: Plainly, some links on this page are affiliate links. Buying through them may earn us a commission. There is no extra cost to you.
Are BPC-157 and TB-500 on the 2026 WADA list?
Men's Fitness, in a Men's Fitness article from Nov. 15, 2026, reports that the 2026 WADA prohibited list bans BPC 157, TB 500 and MOTS c.
Muscle & Fitness is a first-person commentary, so its views are the author's opinion. Its factual statement is that BPC-157 and TB-500 remain prohibited under WADA rules, and that USADA has already sanctioned athletes over these compounds.
Men's Fitness also includes MOTS-c in its list. The Muscle & Fitness statement names BPC-157 and TB-500. Before you rely on either list, check the current WADA Prohibited List for your sport. For the athlete-specific rules on BPC-157, read our is bpc 157 banned for athletes page.
Quick facts as of 2026-11-16
| Item | What the sources say | Source |
|---|---|---|
| 2026 WADA list | Lists BPC 157, TB 500 and MOTS c as banned | Men's Fitness, Nov. 15, 2026 |
| WADA rules for BPC-157 and TB-500 | Remain prohibited; USADA has sanctioned athletes over these compounds | Muscle & Fitness commentary, Nov. 16, 2026 |
| Status of the HHS policy | Draft enforcement discretion policy on 503A compounding; not FDA-approved | Federal Register notice, published Oct. 30, 2026 |
| Peptides covered | BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax | Drug Topics, Nov. 16, 2026; Men's Fitness; Muscle & Fitness |
| Who may compound under the policy | State-licensed pharmacies, federal facilities and licensed physicians | Federal Register notice |
| Prescription in sport | A prescription does not make a substance permissible for tested athletes | Men's Fitness, Nov. 15, 2026 |
What the HHS peptide policy covers
The Federal Register notice on peptide compounding was filed for public inspection on Oct. 28 and published on Oct. 30, 2026. It says HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A.” The notice itself names no peptides. They sit in Appendix A.
Drug Topics, Men's Fitness and Muscle & Fitness all name the same six: BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax. Drug Topics says the pharmacies must be state-licensed 503A pharmacies that meet quality standards and route limits. Men's Fitness says the conditions include a patient-specific prescription and documentation of ingredient identity.
The notice says compounded drugs “are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” It also says the draft “does not establish any rights for any person and is not binding on HHS or the public.” This is enforcement discretion, not FDA approval.
Does the HHS policy change sport anti-doping rules?
Based on the reporting, no. Men's Fitness says a prescription does not make a substance permissible for tested athletes. Muscle & Fitness says the two compounds remain prohibited under WADA rules. The HHS notice covers compounding by pharmacies and licensed physicians. The bans come from the WADA list the outlets cite.
If you're a tested athlete who may need a listed substance for a medical reason, talk with your team physician first. Then check your sport's rules, since they set what applies to your testing program. If you've already taken a product by accident, see accidentally took a banned supplement.
What the research says about BPC-157 and TB-500
A 2026 rat study in Joint Diseases and Related Surgery, listed on PubMed listing of the rat tendon study, tested Achilles tendon repair in 32 male Sprague-Dawley rats. The rats were split into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and the two combined. Treatments ran intraperitoneally for four weeks after surgery.
The TB-500 group showed higher maximum load to failure than controls, a difference the study reports as significant (p < 0.05). Its total Bonar scores were significantly lower (p = 0.016). The BPC-157 group's total scores were numerically lower but did not reach significance. Combining the two added no benefit. The authors call the work exploratory and say both peptides warrant further investigation pending dose optimization and longer-term studies.
A 2026 narrative review in The Journal of the American Academy of Orthopaedic Surgeons, listed on PubMed review of orthopaedic peptide use, searched literature through June 2026. It says BPC-157 has the largest body of direct musculoskeletal preclinical evidence, mostly small-animal studies. Human musculoskeletal evidence is one small retrospective, uncontrolled case series without validated outcome measures. It also says validated dosing, pharmacokinetic and long-term safety data are lacking.
The same review says TB-500 is a seven amino-acid fragment of TB-4 and is “frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence.” For a wider look at what peptide studies cover, see peptides safety evidence (our research library).
What safety concerns has FDA raised?
These are the concerns as each outlet reports them:
- The Federal Register notice says compounded drugs “also may pose risks to patients.”
- Men's Fitness reports that FDA has identified potential safety concerns with compounded peptides, including immune reactions and impurities, and says it lacks important safety information for some substances.
- Drug Topics reports that FDA scientific reviewers previously concluded none of the nominated peptides met the statutory criteria for the bulk drug list, citing limited human clinical trial data and uncertainty about product characterization.
- Muscle & Fitness reports that FDA scientists raised concerns about lack of convincing clinical data and product safety.
- The UCSD Guardian, a student opinion column, says FDA has described risks for BPC-157 such as unwanted immune reactions.
Drug Topics also quotes Brigid Groves, PharmD, MS, of the American Pharmacists Association, who says the association's comments state that evidence is still insufficient for clinicians to counsel patients confidently on long-term safety, drug interactions and outcomes.
Who does this affect?
- Tested athletes. Men's Fitness reports that a prescription does not make a substance permissible for tested athletes.
- Lifters and runners outside a testing program. The policy is mostly about who can compound and prescribe these peptides, plus what the research and regulators say about them.
- People asking about a prescription. Men's Fitness interviews Dr. Alex Tatem, who works with the telehealth company Rugiet, according to the article. Tatem says doctors may prescribe the listed peptides through licensed compounding pharmacies under the policy's conditions, and he advises against treatment for people with active cancer. These are his views, and he has a commercial tie to the telehealth company.
Key dates
| Date | What happened | Source |
|---|---|---|
| Oct. 28, 2026 | Notice filed for public inspection; the UCSD Guardian says HHS announced the policy this day | Federal Register; UCSD Guardian |
| Oct. 30, 2026 | Published in the Federal Register (91 FR 68526) | Federal Register notice |
| Nov. 13, 2026 | Two-week comment window ends | Federal Register notice |
| Nov. 15–16, 2026 | Coverage in Men's Fitness, Drug Topics and Muscle & Fitness | Outlets named above |
| Nov. 16, 2026 | Regulations.gov showed 289 comments received on the docket | Regulations.gov docket HHS-OASH-2026-0496 |
Common mix-ups
- Draft or interim? The Federal Register calls it a draft. Men's Fitness's headline calls it an interim enforcement policy. Both describe the same policy.
- Allowed or approved? Enforcement discretion is not FDA approval. The notice says these compounded drugs are not FDA-approved.
- TB-500 or TB-4? The orthopaedic review treats them as different products. TB-500 is a fragment, not the full-length molecule.
- A prescription or a sport ban? Men's Fitness says a prescription does not make a substance permissible for tested athletes.
- Compounded or research-use-only? Drug Topics says patients are buying these peptides through gray-market “research-use-only” sources online. That's a different channel from the compounding policy. For more on contaminated products, see contaminated supplements banned substances.
Questions to ask your team physician or sports doctor
The orthopaedic review says clinicians should ask about peptide use and counsel athletes about antidoping restrictions. Bring these questions:
- Are BPC-157 or TB-500 on the 2026 WADA list that applies to my sport and testing program?
- If a prescription were written, how would it change my status under my sport's rules?
- If I had a medical reason to need a listed substance, what do my sport's rules say I should do?
- Where would a compounded product come from, and can the pharmacy show the bulk ingredient's source and certificate of analysis?
- What does the research, which is mostly animal studies, mean for my injury?
- Would you report any side effects, and how?
Your next step is small. Pull up the WADA list for your sport, then take these questions to your team physician, your prescriber or a pharmacist before you decide anything.
By the Gym Floor Guide Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.